secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001193125-24-246627
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero suspends SPR720 development after Phase 2a miss; cuts workforce 39%, extends cash runway to mid-2026
--------------------------------------------------------------------------------

- SPR720 Phase 2a interim analysis did not meet primary endpoint; 3 cases of reversible grade 3 hepatotoxicity at 1,000 mg dose.
- Company restructuring with ~39% workforce reduction; expects ~$1.1M in cash restructuring charges.
- Unaudited Q3 2024 cash ~$76.3M; cash runway extended into mid-2026.
- Tebipenem HBr PIVOT-PO Phase 3 trial on track for enrollment completion in 2H 2025.
- IND cleared for SPR206 Phase 2 trial in HABP/VABP, contingent on non-dilutive funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312524246627/0001193125-24-246627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312524246627/d889032d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-246627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer